论文部分内容阅读
目的探讨胃癌淋巴结微转移的基因诊断方法,分析CK19 mRNA、MUC1 mRNA作为胃癌微转移检测分子标志物的可行性。方法应用逆转录-聚合酶链反应(RT-PCR)方法检测52例胃癌462枚常规病理阴性淋巴结中黏蛋白1(MUC1)mRNA、细胞角蛋白19(CK19)mRNA表达;对照组为4例胃良性病变患者的38枚淋巴结。结果胃良性病变患者38枚淋巴结中CK19 mRNA和MUC1 mRNA表达均为阴性;CK19、MUC1 mRNA在胃癌患者462枚常规病理阴性的淋巴结中223枚(48.3%)阳性表达,其中180枚(39.0%)淋巴结CK19 mRNA阳性表达,136枚(29.4%)MUC1 mRNA阳性表达,CK19 mRNA和MUC1 mRNA均为阳性者有125枚(27.0%)。不同组织类型淋巴结CK19、MUC1 mRNA阳性率差异无显著性(P>0.05),不同肿瘤浸润层次、原发肿瘤大小、肿瘤位置的阳性率差异有显著性(P<0.05)。结论MUC1、CK19基因均可作为RT-PCR法检测胃癌患者淋巴结微转移的分子标志物。
Objective To investigate the gene diagnosis of lymph node micrometastases in gastric cancer and to analyze the feasibility of using CK19 mRNA and MUC1 mRNA as molecular markers for micrometastasis in gastric cancer. Methods Mucin 1 (MUC1) mRNA and cytokeratin 19 (CK19) mRNA were detected by RT-PCR in 462 gastric cancer specimens from 52 patients with gastric cancer. The control group consisted of 4 gastric 38 lymph nodes in patients with benign lesions. Results CK19 mRNA and MUC1 mRNA expression were negative in 38 lymph nodes of gastric benign lesions. CK19 and MUC1 mRNA were positively expressed in 462 routinely pathologically negative lymph nodes of gastric cancer (48.3%), of which 180 (39.0%) were positive The positive expression of CK19 mRNA in lymph nodes, positive expression of MUC1 mRNA in 136 (29.4%), 125 (27.0%) of positive CK19 mRNA and MUC1 mRNA. There were no significant differences in the positive rates of CK19 and MUC1 mRNA between different types of lymph nodes (P> 0.05). There were significant differences in the positive rates of tumor size and tumor location between different tumor types (P <0.05). Conclusion Both MUC1 and CK19 genes can be used as molecular markers for detecting lymph node micrometastasis in gastric cancer patients by RT-PCR.